Dr. Weeks’ Comment: If you were the sheriff called in to control a mob you would not spend your time arresting the by-standers, you’d focus on the ringleader. It is the same with cancer. Tragically, ignoring fast-breaking research, most oncologists persist in targeting the bystanders (the cancer TUMOR cells) and are not addressing the ringleaders (cancer STEM cells) which are the only cells which metastasize and which are the lethal cells. Having learned from the leaders in oncology today Dr. Robert Weinberg, Dr. Max Wicha, and Dr. Michael Clark on this revolutionary topic, I have lectured to medical colleagues on 4 continents – targeting cancer STEM cells for the past 8 years and fortunately, people are catching on. But for YOU today – prior to accepting chemotherapy and or radiation – treatments with Dr. Wicha claims “make your cancer worse” – ask your oncologist 3 questions
1) what will your proposed treatment do to my cancer STEM cells?
2) what will you do to nourish me and my immune system while you strive to kill my cancer TUMOR cells
3) if your current proposed protocol fails, what are your next proposed treatments?
Below, you are invited read about prostate cancer STEM cells
Targeting prostate cancer STEM cells … finally! Posted by Bradford S. Weeks, MD on September 28, 2011. Dr. Weeks’ Comment: the cancer doctors are in …
Aug 17, 2011 … Scientists from Sweden are working on a treatment which attacks stem cell-like cells inprostate cancer. The technology could be useful for …
Nov 27, 2013 … Drs. Goldstein, Witte and colleagues previously reported in Science that prostatecancer can start in basal type stem cells. Building on that …
Apr 17, 2011 … Therapeutic Implications of the Cancer Stem Cell Hypothesis …. those arising in the brain, prostate, colon, head and neck, pancreas, and liver.
Scientists Identify Prostate Cancer Stem Cells Among Low-PSA Cells
|Low-PSA Prostate Cancer Stem Cell,
Tang et al, Cell Stem Cell Volume 10, Issue 5.
|PSA-Positive Cells Dividing Rapidly
Tang et al, Cell Stem Cell Volume 10, Issue 5.
Prostate cancer cells that defy treatment and display heightened tumor-generating capacity can be identified by levels of prostate specific antigen (PSA) expressedin the tumor cells, a research team led by scientists at The University of Texas MD Anderson Cancer Center reports in the May 3 edition of Cell Stem Cell.
“Using a new technique, we were able for the first time to separate low-PSA and high-PSA prostate cancer cells. This led to the discovery of a low-PSA population of cancer stem cells that appears to be an important source of castration-resistant prostate cancer,” said study senior author Dean Tang, Ph.D., professor in MD Anderson’s Department of Molecular Carcinogenesis.
Hormone therapy is used to block production of testosterone, which fuels prostate cancer growth, via either chemical or physical castration. Tumors eventually resist this approach.
In cell lines and mouse model experiments, the low-PSA cells resisted chemotherapy and thrived under hormone deprivation, the two main prostate cancer drug treatments , the researchers found.
Low-PSA cells were found to be both self-renewing and capable of differentiating into other prostate cancer cell types upon division, a hallmark of stem cells called asymmetric cell division.
“Asymmetric cell division is the gold standard feature of normal stem cells,” Tang said. “Using time-lapse fluorescent microscopy, we were able to show asymmetric cell division by filming a low-PSA cell dividing into one high-PSA cell and one low-PSA cell.”
Their findings point to the need to develop new therapeutics to target low-PSA prostate cancer cells that can be combined with hormone therapy to wipe out cancer cells and prevent recurrence.
Low-PSA tumors associated with advanced prostate cancer
Previous research by others indicated that low-PSA tumor cells are rare in early stage disease but become more abundant in advanced prostate cancer. And patients whose tumors were composed of more than 50 percent PSA-positive cells enjoyed longer survival.
This made Tang and colleagues wonder whether the two cell types fundamentally differ from each other and so play different roles in prostate cancer progression.
They analyzed 20 untreated prostate cancer samples staged at varying degrees of aggressiveness on the Gleason scale and 23 samples where treatment had failed. High-PSA tumor cells composed on average about 80 percent of the Gleason 7 tumors, about 60 percent of the higher grade Gleason 9/10 tumors but only about 15 percent of the treatment-failed tumors.
A database analysis of gene expression in prostate cancer was consistent with the tumor experiments, indicating an association between low levels of PSA in tumors and disease recurrence, spread to lymph nodes, metastasis and shortened patient survival.
Turning high-PSA cells green
The next challenge was separating the two cell types to understand their biological, tumor-initiating and drug-response properties.
Tang and colleagues developed a lentiviral delivery system equipped with a PSA promoter that triggers green fluorescence protein when PSA is expressed in an infected cell.
This lentiviral reporter system allowed separation of low-PSA and high-PSA cells for the first time, Tang said. A series of experiments uncovered striking differences between them.
High-PSA prostate cancer cells:
- Divide rapidly, which makes them vulnerable to chemotherapy that targets fast-proliferating cells;
- Express high levels of the androgen receptor, a key to testosterone production, and so are vulnerable to hormonal therapy; and
- Produce only identical copies of themselves when they divide.
Low-PSA prostate cancer cells:
- Divide slowly and express anti-stress genes that help them resist chemotherapy;
- Either lack or have a weak presence of the androgen receptor, allowing them to grow while hormonal therapy wipes out PSA-positive cells; and
- Can divide into one copy of themselves and one PSA-positive cell during reproduction. The researchers captured this on video microscopy, filming the division of a grey low-PSA cell into one copy of itself and one copy of a vibrantly green PSA-positive cell.
Low-PSA tumors have long-term tumor-generating capacity
When the team implanted the two cell types in hormonally intact male mice, the rapidly reproducing PSA-positive cells caused faster growth and larger tumors in the first generation. However, after that the low-PSA cells generated larger, faster-growing tumors and tumor incidence in the high-PSA cells dropped. In fact, the low-PSA prostate cancer cells possess indefinite tumor-propagating capacity.
In contrast, when implanted in the castrated mice, the low-PSA prostate cancer cells developed much larger tumors than the corresponding high-PSA cells. In another experiment, mice with tumors generated by either cell type were then castrated and treated with hormonal therapy. Low-PSA tumors grew better in these doubly androgen-deprived mice than the high-PSA tumors.
“These findings closely resemble progression observed in patients after androgen-deprivation treatment and reflect reduced PSA-producing cells in patient tumors after androgen depletion,” Tang said.
Effect of low-PSA cells in human tumors
Tang and colleagues analyzed tumor cell PSA expression in 556 human tumors and found low protein levels correlated with reduced overall survival.
They separated the two types of cells in three primary human tumors and found that low-PSA cells did not express androgen receptor and have higher cell-generating and sphere-forming capabilities than high-PSA cells.
Future research will focus on developing therapeutic targets for low-PSA cells and illuminating the epigenetic landscapes of both cell types.
Co-authors with Tang are co-first authors Jichao Qin, Ph.D., and Xin Liu, Ph.D., Brian Laffin, Ph.D., Xin Chen, M.D., Grace Choy, Ph.D., Collene Jeter, Ph.D., Tammy Calhoun-Davis, Hangwen Li, Ph.D., Kevin Lin, and Mahipal Suranen, Ph.D., all of MD Anderson’s Department of Molecular Carcinogenesis at the Science Park in Smithville, Texas; Ganesh Palapattu, M.D., The Methodist Hospital, Houston; Shen Pang, Ph.D., UCLA Dental Research Institute and School of Dentistry; Jiaoti Huang, M.D.,Ph.D., UCLA David Geffen School of Medicine; Ivan Ivanov, Ph.D., Texas A&M University College of Veterinary Medicine; and Wei Li, Ph.D., Baylor College of Medicine, Houston.
This research was financed by grants from the National Cancer Institute, the U.S. Department of Defense, the Cancer Prevention and Research Institute of Texas, the Elsa Pardee Foundation, the MD Anderson Cancer Center University Cancer Fund, MD Anderson Center for Cancer Epigenetics, the Laura and John Arnold Foundation and MD Anderson’s Cancer Center Support Grants.